Trial reportObesity surgery2025
Endoscopic Band Ligation for Weight Loss: A Clinical Trial.
Trial report in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07117721 (Evaluation of Endoscopic Band Ligation for Treatment of Type 2 Diabetes), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Endoscopic Band Ligation for Treatment of Type 2 Diabetes: A Single-Center Interventional Study
Who cites it
1 citing paper in PubMed.
- Endoscopic Band Ligation for Weight Loss: Exploring the Gastric Antrum as a Promising Target.Obesity surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimWe previously reported the utility of endoscopic band ligation (EBL) in weight loss in a female patient with obesity. This study aimed to evaluate the safety of weight loss using EBL in a larger cohort. PATIENTS AND
methodsThis prospective cohort study included 13 female patients aged ≥ 18 years with a body mass index of ≥ 30 kg/m
resultsNo serious complications occurred during the endoscopy or immediately after that. All patients experienced epigastric pain, nausea, and vomiting for the first 3 days, with one patient developing mild hematemesis on the second day that stopped spontaneously and revealed no abnormalities on endoscopy. At 1 month after EBL, the mean percent excess weight loss and total weight loss were 22.3% ± 9.9% and 7.8% ± 2.5%, respectively.
conclusionsEBL is an effective and safe intervention for obesity management. Further studies with larger cohorts are warranted to comprehensively evaluate of the long-term efficacy and safety of EBL for obesity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.